

Diffuse Large B Cell Lymphoma Therapeutics Market Size, Trends, Analysis, and Outlook By Product (Small molecules, Biologics), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/D87E8A206AD9EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: D87E8A206AD9EN

Abstracts

The global Diffuse Large B Cell Lymphoma Therapeutics market size is poised to register 8.84% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Diffuse Large B Cell Lymphoma Therapeutics market By Product (Small molecules, Biologics), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others).

The future of diffuse large B-cell lymphoma (DLBCL) therapeutics is characterized by advancements in targeted therapies, immunotherapy agents, and combination treatment approaches aimed at improving response rates, progression-free survival, and overall survival outcomes in patients with DLBCL, the most common subtype of non-Hodgkin lymphoma (NHL). Key trends shaping this market include the development of novel monoclonal antibodies, such as rituximab, obinutuzumab, and polatuzumab vedotin, that target CD20-expressing B cells, enhance antibody-dependent cellular cytotoxicity (ADCC), and induce complement-dependent cytotoxicity (CDC) to eliminate malignant lymphocytes, reduce tumor burden, and prolong remission durations in DLBCL patients when used alone or in combination with chemotherapy regimens, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Moreover, there is a trend towards immunomodulatory agents, such as immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or

programmed death-ligand 1 (PD-L1), and chimeric antigen receptor (CAR) T cell therapies that harness the power of the immune system to recognize and eradicate lymphoma cells, overcoming immune evasion mechanisms, enhancing T cell activation, and inducing durable responses in refractory or relapsed DLBCL patients who have failed standard therapies. Additionally, there is a growing emphasis on biomarker-driven treatment strategies and precision oncology approaches that identify DLBCL subgroups with specific genetic alterations, cell of origin (COO) subtypes, or molecular signatures, enabling targeted therapy selection, risk stratification, and treatment optimization based on individual tumor biology, genetic profiling, and predictive biomarkers, such as MYC, BCL2, and BCL6 rearrangements, TP53 mutations, or tumor microenvironment (TME) characteristics, to improve patient outcomes and minimize treatment toxicity in DLBCL management..

Diffuse Large B Cell Lymphoma Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Diffuse Large B Cell Lymphoma Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Diffuse Large B Cell Lymphoma Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Diffuse Large B Cell Lymphoma Therapeutics industry.

Key market trends defining the global Diffuse Large B Cell Lymphoma Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Diffuse Large B Cell Lymphoma Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Diffuse Large B Cell Lymphoma Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche

segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Diffuse Large B Cell Lymphoma Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Diffuse Large B Cell Lymphoma Therapeutics industry

Leading Diffuse Large B Cell Lymphoma Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Diffuse Large B Cell Lymphoma Therapeutics companies.

Diffuse Large B Cell Lymphoma Therapeutics Market Study- Strategic Analysis Review

The Diffuse Large B Cell Lymphoma Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Diffuse Large B Cell Lymphoma Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Diffuse Large B Cell Lymphoma Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Diffuse Large B Cell Lymphoma Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Diffuse Large B Cell Lymphoma Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Diffuse Large B Cell Lymphoma Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Diffuse Large B Cell Lymphoma Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Diffuse Large B Cell Lymphoma Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating

in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Diffuse Large B Cell Lymphoma Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Diffuse Large B Cell Lymphoma Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Diffuse Large B Cell Lymphoma Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Diffuse Large B Cell Lymphoma Therapeutics.

Diffuse Large B Cell Lymphoma Therapeutics Market Company Profiles

The global Diffuse Large B Cell Lymphoma Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing

to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, ADC Therapeutics SA, Bayer AG, BeiGene Ltd, Bristol-Myers Squibb Co., Celltrion Healthcare Co. Ltd, CTI BioPharma Corp, Erytech Pharma SA, F. Hoffmann La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc, Novartis AG, Pfizer Inc.

Recent Diffuse Large B Cell Lymphoma Therapeutics Market Developments

The global Diffuse Large B Cell Lymphoma Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Diffuse Large B Cell Lymphoma Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

AbbVie Inc

ADC Therapeutics SA

Bayer AG

BeiGene Ltd

Bristol-Myers Squibb Co.

Celltrion Healthcare Co. Ltd

CTI BioPharma Corp

Erytech Pharma SA

F. Hoffmann La Roche Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Johnson and Johnson

Merck and Co. Inc

Novartis AG

Pfizer Inc

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Diffuse Large B Cell Lymphoma Therapeutics Market Overview and Key Findings, 2024
- 1.2 Diffuse Large B Cell Lymphoma Therapeutics Market Size and Growth Outlook, 2021- 2030
- 1.3 Diffuse Large B Cell Lymphoma Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Diffuse Large B Cell Lymphoma Therapeutics Market Trends and Challenges
 - 1.4.1 Diffuse Large B Cell Lymphoma Therapeutics Market Drivers and Trends
 - 1.4.2 Diffuse Large B Cell Lymphoma Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Diffuse Large B Cell Lymphoma Therapeutics Companies

2. DIFFUSE LARGE B CELL LYMPHOMA THERAPEUTICS MARKET SIZE OUTLOOK TO 2030

- 2.1 Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook, USD Million, 2021- 2030
- 2.2 Diffuse Large B Cell Lymphoma Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. DIFFUSE LARGE B CELL LYMPHOMA THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. DIFFUSE LARGE B CELL LYMPHOMA THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

4.1 Market Segmentation and Scope

4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Diffuse Large B Cell Lymphoma Therapeutics Market, 2025

5.2 Asia Pacific Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by

Application, 2021- 2030

5.4 Key Findings for Europe Diffuse Large B Cell Lymphoma Therapeutics Market, 2025

5.5 Europe Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.6 Europe Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Diffuse Large B Cell Lymphoma Therapeutics Market, 2025

5.8 North America Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Diffuse Large B Cell Lymphoma Therapeutics Market, 2025

5.11 South America Pacific Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Diffuse Large B Cell Lymphoma Therapeutics Market, 2025

5.14 Middle East Africa Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

6.1 US Diffuse Large B Cell Lymphoma Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities

- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities

- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Diffuse Large B Cell Lymphoma Therapeutics Industry Drivers and Opportunities

7. DIFFUSE LARGE B CELL LYMPHOMA THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. DIFFUSE LARGE B CELL LYMPHOMA THERAPEUTICS COMPANY PROFILES

- 8.1 Profiles of Leading Diffuse Large B Cell Lymphoma Therapeutics Companies in the Market
 - 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
 - 8.3 Financial Performance and Key Metrics
- AbbVie Inc
- ADC Therapeutics SA
- Bayer AG
- BeiGene Ltd
- Bristol-Myers Squibb Co.
- Celltrion Healthcare Co. Ltd
- CTI BioPharma Corp
- Erytech Pharma SA
- F. Hoffmann La Roche Ltd
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Johnson and Johnson
- Merck and Co. Inc

Novartis AG
Pfizer Inc

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

I would like to order

Product name: Diffuse Large B Cell Lymphoma Therapeutics Market Size, Trends, Analysis, and Outlook By Product (Small molecules, Biologics), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/D87E8A206AD9EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D87E8A206AD9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970